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Todeterminehowareductioninmaternalhypertriglyceridemia
during late pregnancy may affect glucose/insulin relationships,
pregnantandvirginratswereorallytreatedwithacipimox,apotent
antilipolyticagent.In20-daypregnantratsreceiving80mgofacip-
imox, plasma triglycerides (TG), free fatty acids (FFA), and glyc-
eroldecreasedmorethaninvirginratsshortlyafterthedrug(upto
7 hours),when compared with animalstreatedwith distilledwater,
whereas plasma glucose level was unaffected by the treatment in
eithergroupofrats.Whenacipimoxwasgivenevery12hoursfrom
day 17 to day 20 of pregnancy, plasma TG, FFA, and glycerol levels
progressively increased, whereas they either decreased or did not
changeinvirginratsreceivingthesametreatment,withnoeffectin
plasma glucose levels in either group. Fetal body weight was lower
than in controls in 20-day pregnant rats that received acipimox for
3 days. On day 20 of pregnancy, 3 hours after receiving acipimox
ordistilledwater,ratsreceiveda2gglucose/kgoralloadanditwas
foundthatthechangeinplasmaglucosewassimilarinbothgroups,
whereastheincreaseinplasmainsulinwasgreaterinpregnantrats
treated with acipimox. However, no difference was found in either
variable after the oral glucose load in virgin rats receiving acipi-
mox or distilled water. No differences in plasma glucose levels were
found after intravenous (IV) administration of insulin in pregnant
rats treated or not treated with acipimox. In conclusion, present
results show that administration of acipimox during the last days
of gestation inhibited lipolysis and decreased fetal weight. Over a
short period of time, in pregnant rats, reductions of plasma FFA
and TG after acipimox treatment improved the glucose-induced
insulin release, but did not seem to have any effect in peripheral
insulin resistance.
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The enhanced lipolytic activity present during late gestation
gives rise to an elevation in plasma free fatty acids (FFA) and
triglycerides (TG), both in women and rats [1–3]. Some tissues
usefattyacidsasfuel,sparingglucoseforthefast-growingfetus
and those maternal tissues that can only use glucose as fuel
energy [4]. The mechanisms involved in this elevated lipolytic
activity are uncertain, but the rising levels of placental lactogen
and the insulin resistance during late pregnancy seem to play a
relevant role [5–7].
The enhanced availability of FFA to the liver seems to con-
tribute to the increased production of TG by this organ [8] and
therefore to the development of maternal hypertriglyceridemia.
Exaggerated increment of TG in maternal circulation may be
involved in some of the pregnancy-induced complications, in-
cluding eclampsia [9] and insulin resistance that would cause
the development of gestational diabetes [7], 2 of the most com-
mon pregnancy-induced complications. Therefore, decreasing
the hypertriglyceridemia of late pregnancy may be of therapeu-
tic use. Nevertheless, this therapeutic approach may not be risk
free for the fetus, because in human pregnancies maternal TG
have a positive correlation with the newborn weight [10], and
decreased lipid levels have been associated with intrauterine
growth retardation [11]. To test how a decline in FFA and TG
duringlatepregnancyaffectsmaternalglucose/insulinrelations,
we studied the effects of acipimox, a powerful inhibitor of lipol-
ysis [12–14] in late pregnant rats, when adipose tissue lipolytic
activity is enhanced.
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METHODS AND EXPERIMENTAL DESIGN
Animals
Female virgin Wistar rats from our own colony, weighing
190 to 220 g, were housed in a temperature-controlled room
(22±CC1±C)withalternating12-hourlightanddarkcycles,and
fed a Purina Chow diet (Rat and Mouse standard diet, Beekay
Feeds,B.K.UniversalS.L.,Barcelona,Spain).Thecareandhan-
dling of the animals throughout the study followed the current
law for Animal Care of the European Community (Strasburg,
March 18, 1986). The rats were mated and the day that sperm
appeared in the vaginal smears was considered day 0 of ges-
tation, when rats were divided into 2 different experimental
groups.
Experiment 1
Todeterminethehypolipemiceffectsofacipimoxduringlate
pregnancy, 20-day pregnant rats were divided in 2 experimental
groups.Ratsfrom1groupreceivedbygavage80mgofacipimox
(Farmitalia Carlo Erba, Milano, Italy) diluted in 0.3 mL of dis-
tilled water, whereas those from the second group received the
same amount of distilled water. Two groups of virgin rats were
also studied in parallel under the same experimental conditions.
Fromthemomentoftreatment,theanimalswerekeptfastedand
blood samples were obtained before and 1.5, 3, 5, and 7 hours
thereafter. FFA, glycerol, TG, and glucose were determined.
Experiment 2
To study whether the daily administration of acipimox from
days17to20ofpregnancy,aperiodofhighlipolyticactivity,was
able to decrease plasma levels of TG and modify fetal growth, 2
groupsofratswereused.Onegroupreceived80mgofacipimox
as above at 9:00 and 21:00 hours during the 3 days of the study.
The second group received distilled water as a control. Two
groups of nonpregnant animals were also studied, in parallel,
underthesameexperimentalconditions.Nodifferenceinweight
gain between 17 and 20 days of pregnancy was observed in
rats treated with acipimox compared with distilled water. Tail
blood was obtained daily between 8:00 and 9:00 AM, just before
the morning treatment, whereas on day 20, the animals were
decapitated and the blood was collected from the neck wound.
The 2 uterine horns were immediately dissected and fetuses and
placenta were excised and weighed.
Experiment 3
To determine whether the reduction of FFA and TG affects
either the oral glucose tolerance test (OGTT) [15] or the intra-
venousinsulintest(IVIT)[15],2newgroupsofpregnantanimals
were studied, one treated with acipimox (80 mg) and the other
with distilled water, as described above for experiment 1. On
day 20 of pregnancy, and after a fasting period of 12 hours, an
OGTT was performed 3 hours after the administration of acip-
imox or distilled water, time of maximum decrease in FFA and
TG, by administering 2 g glucose/kg body weight dissolved in
distilled water by gavage. Blood samples were collected from
thetipofthetailintoheparinizedtubesat0,7.5,15,22,30,60,or
120 minutes after glucose administration. Plasma samples were
kept at ¡20±C until analyzed for glucose and insulin.
In another 2 groups of animals, submitted to the same ex-
perimental conditions as for the OGTT, an IVIT was performed
3 hours after the administration of acipimox, through a tail vein,
either 10 IU of Actrapid monocomponent porcine insulin (from
Novo Industry A/S) dissolved in 1 mL 0.9% NaCl/kg of body
weight or 1 mL of 0.9% NaCl/kg. Blood samples were obtained
from the tail, before the administration of insulin and 4, 8, 12,
16, and 32 minutes thereafter.
Blood Collection
BloodwascollectedinEDTA(1mg/mL)fromthetailorfrom
the open neck after decapitation. The blood was centrifuged at
2500 rpm and plasma stored at ¡20±C until processed.
Analysis of the Samples
Glucose, FFA, and TG were determined using commer-
cially available kits: Glucose God-Pad Enzymatic Clorimetric
test (Boehringer Mannheim, Mannheim, Germany) for glucose;
NEFA C ACS, acid method (Wako Chemical, Neuss, Germany)
forFFA;andTriglyceridesEnzymaticTrindermethod(Menarini
Diagnostics, Florence, Italy) for TG. Glycerol was determined
usingaﬂuorimetricmethod[16].Arat-speciﬁcradioimmunoas-
say kit from Incstar (Stillwater, Minnesota, USA) was used to
determine the insulin.
Statistical Analysis
Means§SE are given. The signiﬁcance of the difference be-
tween the 2 groups was obtained using the analysis of variance
and Tuckey test. When samples from the same animals were
studied, a paired t test was applied. Statistical analysis was per-
formed using Systat program (Systat, Evanston, Illinois, USA).
RESULTS
Experiment 1
In 20-day pregnant animals, 3 hours after the oral admin-
istration of distilled water and of the onset of fasting, an in-
crease in plasma FFA and glycerol was observed (Figure 1).
However, the administration of acipimox impeded the eleva-
tion of both variables at least for 7 hours (Figure 1). RegardingLIPIDS AND GLUCOSE/INSULIN IN ACIPIMOX-TREATED PREGNANT RATS 235
FIGURE 1
Effect of acipimox on plasma TG, glycerol, FFA, and glucose in 20-day pregnant and virgin rats. Eighty milligrams of acipimox in
0.3 mL of distilled water were administered by gavage to 20-day pregnant rats and the same amount of distilled water as placebo.
Two additional groups of virgin animals were studied under the same experimental conditions. The values are means§SE of
13 animals. The differences between animals treated with acipimox versus placebo: ¤P<.05; ¤¤P<.01; ¤¤¤P<.001. Solid lines
with solid circles represent animals treated with acipimox; dashed lines with open circles represent the placebo group.
TG, in the group treated with distilled water, plasma concen-
tration of TG remained practically stable during the 7 hours of
study (Figure 1). However, in the group treated with acipimox,
a marked decrease in plasma concentration of TG was observed
after1.5hours,andthelevelsremainedlowerthaninthecontrol
group during the 7 hours of the study. In nonpregnant animals,
as expected, basal levels (time 0) of FFA, glycerol, and TG were
lowerthaninpregnantanimals(Figure1).Invirginratsreceiving
distilled water, a rise in plasma levels of FFA and glycerol was
observed after 5 hours of the initiation of the study. This effect
was not observed in the acipimox-treated group (Figure 1). In
eitherpregnantorvirginanimals,theadministrationofacipimox236 I. S´ ANCHEZ-VERA ET AL.
did not lead to any changes in the plasma concentration of glu-
cose during the 7 hours of the study.
Experiment 2
Daily administration of acipimox during days 17 to 21 of
pregnancy led to a decrease in fetal weight: 4.11§0.12 g in
fetuses from rats treated with acipimox versus 4.46§0.21 g in
fetus from the control group (P<.001). As expected, during
the last days of pregnancy in the group receiving distillated wa-
ter, the concentration of TG and FFA raised steadily with time,
whereas no changes were observed in plasma glycerol levels
(Table1).Whenacipimoxwasadministeredevery12hoursdur-
ing the 17th to the 20th days of pregnancy, an increase in FFA,
glycerol, and TG was observed. FFA and glycerol reach levels
similar to or even higher than those observed in rats receiving
distilled water; the level of TG was slightly lower for acipimox-
treated pregnant rats. In virgin animals, the administration of
acipimox every 12 hours during 3 days did not have any effect
on plasma levels of FFA and glycerol, and decreased the levels
of TG compared with values observed in virgin animals treated
with distilled water. No changes were found in plasma glucose
levelsofbothpregnantandvirginanimalstreatedwithacipimox
during the 3 days of the experiment (Table 1). As expected, glu-
cosevaluesofthepregnantratswerelowerthaninvirginanimals
(Table 1).
TABLE 1
Plasma levels of TG, FFA, glycerol, and glucose in pregnant and virgin rats treated with either acipimox or distilled water
Pregnant rats Virgin rats
Hours after the
begining of treatment Acipimox Placebo Acipimox Placebo
Triglycerides (mg/dL) 0 250.7§15.5 267.1§22.5 187.8§17.1 175.5§14
24 253.1§19.8 312.1§28.3 151.7§19.9 170.0§20.6
48 357.0§35.1¤ 391.8§41.2¤ 119.3§15¤¤ 145.1§13.4¤
72 396.7§41.2¤¤ 459.9§60.6¤¤ 108.5§8.6¤¤ 158.1§7.5
Free fatty acid (¹mol/L) 0 473.2§53.9 544.1§45.2 477.1§45.6 555.9§38.7
24 934.9§53.5¤¤¤ 621.9§25.4 833.0§74.6¤¤ 661.5§36.4
48 1220.9§67.7¤¤¤ 832.1§64.8¤¤ 891.5§86.6¤¤¤ 668.6§35.7
72 1239.6§62.4¤¤¤ 907.9§91.9¤¤¤ 659.3§81.8¤ 621.4§26.5
Glycerol (¹mol/L) 0 77.8§9.5 97.2§20.1 82.6§14.7 63.4§14.9
24 104.4§18.3¤¤ 87.6§19.7 93.9§19.9 84.6§13.6
48 122.6§25.5¤¤ 123.3§33.5 117.8§21.5¤ 70.6§19.9
72 154.8§26.4¤¤¤ 99.0§21.7 111.7§20.1¤ 127.6§19.8
Glucose (mg/dL) 0 74.4§2.4 70.8§3.4 90.4§4.4 90.9§3.4
24 71.8§2.8 75.6§3.1 86.9§4.2 87.6§7.1
48 68.6§2.3 69.8§1.6 97.2§4.8 88.9§3.2
72 76.1§2.3 73.7§2.2 112.1§7¤¤¤ 103.6§5.5
Note. Pregnant and virgin rats were treated from days 17 to 20 with either acipimox (80 mg/12 h) or distilled water, as described in “Methods
and Experimental Design.” Values are means§SE of 12 animals. Differences between the values observed before the initiation of the treatment
and thereafter: ¤P <.05; ¤¤P <.01; ¤¤¤P <.001.
Experiment 3
We also wanted to determine whether the decrease in plasma
concentration of TG and FFA secondary to the administration
of acipimox had any effect either in the OGTT or in the IVIT
in 20-day pregnant rats, at the time of increased insulin resis-
tance [15]. As can be seen in Figure 2, after the administration
of oral glucose, no differences were observed in plasma glucose
concentration between control and acipimox groups, in either
pregnant or virgin rats. However, in the acipimox-treated an-
imals, a higher increase in plasma insulin was seen after the
OGTT in pregnant animals than in the control group, but not
in virgin rats (Figure 2). No difference in the plasma glucose
concentration after the IVIT was found between the pregnant
animals treated with acipimox and the control group (Figure 3).
DISCUSSION
Both in humans and rats, at the end of pregnancy, there are
increased levels of plasma TG and FFA [1–3]. These metabolic
substrates can be utilized by most maternal tissues, sparing glu-
cose for glucose-obligatory tissues. In our experiments, as ex-
pected, because of the high lipolytic activity [1–3], in 20-day
pregnant rats, plasma levels of FFA, glycerol, and TG were
higher than in virgin animals. The administration of acipimox
to 20-day pregnant rats decreased the plasma levels of FFA,
glycerol, and TG by >50%. Thus, our results show that, duringLIPIDS AND GLUCOSE/INSULIN IN ACIPIMOX-TREATED PREGNANT RATS 237
FIGURE 2
Results of an OGTT in 20-day pregnant rats treated with a single dose of acipimox or placebo, as described in Figure 1. Two
grams of glucose per kilogram body weight were administered 3 hours after receiving the acipimox treatment, when lower levels
of FFA and TG are present. Results are presented as percentage of basal levels. Solid lines with solid circles represent the animals
treated with acipimox; dashed lines with open circles represent the placebo group. Values are means§SE of 10 animals.
Differences between animals treated with acipimox versus placebo: ¤P<.05; ¤¤P<.01; ¤¤¤P<.001.
pregnancy in rats, acipimox may be used acutely to decrease
plasma levels of FFA and TG.
When acipimox was administered every 12 hours during the
last 3 days of pregnancy, a rebound effect was observed, as it is
FIGURE 3
Under the same conditions described in Figure 2, an IVIT was
performed. The same groups as in Figure 2 received either
1 mL/kg body weight of a solution of 10 IU regular insulin/mL
or 0.9% NaCl. Solid lines with solid circles represent the
animals treated with acipimox and the dashed lines with open
circles represent the placebo group. Values are means§SE of
10 animals. No statistical differences between the 2 groups
were found at any time frame.
shown here by the higher levels of FFA and glycerol observed
12 hours after the administration of acipimox, when compared
withvaluesobservedintheplacebogroup.Thiscontrastswithno
rebound effect observed in virgin animals, when acipimox was
given every 12 hours. Similar results have been shown by our
group with fenoﬁbrate, another TG-reducing compound [17].
The differences in the rebound effect between pregnant and vir-
gin animals could be secondary to the high lipolytic activity
present at the end of gestation, therefore the equilibrium be-
tweentheinhibitoryeffectsofacipimoxonlipolysisareoverrun
by the lipolytic effects of the high levels of (hPL) or the insulin
resistance at late pregnancy [5, 6].
During late gestation, one of the main sources of fuel en-
ergy for the maternal tissues are FFA derived from lipolysis
of very-low-density lipoprotein (VLDL)-TG [4]. Therefore, the
reduction in fetal weight observed on acipimox treatment dur-
ing the last 3 days of pregnancy could be expected as plasma
levels of both FFA and TG decreased. These data are in agree-
ment with the ﬁndings in human pregnancies where a positive
correlation between the maternal levels of plasma TG and the
newborn weight has been observed [10], and the lower weight
observed in newborn from pregnancies with a smaller increase
in plasma cholesterol through pregnancy [11]. Overall, these re-
sults indicate that the elevation of maternal lipid levels through
pregnancy is important to allow the maximal fetal growth. In238 I. S´ ANCHEZ-VERA ET AL.
our experiments, we cannot rule out a direct effect of acipimox
on fetal growth by crossing the placenta. In fact in human pla-
centa perfusates, acipimox crossed the placenta at a slow rate
[18].
Increased levels of FFA and TG have been associated with
insulin resistance [19]. In our experiments, 3 hours after the
administration of acipimox, despite the reduction by >50% of
both FFA and TG, plasma glucose levels observed after OGTT
andIVITweresimilartothevaluesfoundintheuntreatedgroup.
Thus, the reduction of TG and FFA, over a short period of time,
didnotseemtohaveanyeffectintheperipheralinsulinresistance
during late gestation, although we do not know if this is due to
changes in insulin sensitivity when FFA and TG are decreased
over longer period of time. In type 2 diabetes with increased
levels of FFA and TG, the decrease in both by acipimox did not
improve peripheral insulin sensitivity [20].
In our experiments, it is remarkable that in late pregnant rats,
butnotinvirginanimals,wheninsulinresistanceisatitshighest,
theadministrationofacipimox,whichreducedbothFFAandTG
levels, did increase the glucose-induced insulin release during
the OGTT. This result suggests that, during late gestation, the
elevated levels of FFA and TG, under certain circumstances,
could be toxic to the ¯-cell function. In fact, in other conditions
pronetothedevelopmentoftype2diabetes[21–23],theglucose-
induced insulin release is decreased. A similar ﬁnding has been
observed in pregnant women at risk of developing gestational
diabetes [24]. It is attractive to speculate that decreasing FFA
and TG, with acipimox, may constitute a therapeutic approach
to prevent gestational diabetes.
In conclusion, our results show that the administration of
acipimoxduringthelastdaysofgestationinhibitedlipolysisand
decreased fetal weight. Over a short period of time, in pregnant
rats,thereductionofplasmaFFAandTGimprovedtheglucose-
induced insulin release but did not seem to have any effect in
the peripheral insulin resistance.
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